<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40836668</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-2723</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><PubDate><Year>2025</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis</Title><ISOAbbreviation>Clin Appl Thromb Hemost</ISOAbbreviation></Journal><ArticleTitle>Oral Anticoagulant Therapy in Patients with Atrial Fibrillation After Intracranial Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.</ArticleTitle><Pagination><StartPage>10760296251368889</StartPage><MedlinePgn>10760296251368889</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10760296251368889</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/10760296251368889</ELocationID><Abstract><AbstractText>BackgroundThe management of atrial fibrillation (AF) in patients with a history of intracranial hemorrhage (ICH) presents a significant clinical challenge. Although oral anticoagulants (OACs), have been shown to effectively reduce thromboembolic events in AF patients, their use in survivors of ICH raises concerns regarding the risk of recurrent bleeding. In this study, we conduct a systematic review of randomized controlled trials (RCTs) to assess the safety and efficacy of OAC therapy in AF patients following ICH.MethodsWe searched PubMed/Embase for RCTs assessing OACs in AF patients with ICH history. Efficacy outcomes included ischemic stroke, major vascular events, stroke or vascular death, major embolic events, and all-cause mortality.ResultsA total of three RCTs with 623 participants were included. Compared to no anticoagulation or antiplatelet therapy alone, OAC did not significantly reduce the risk of ischemic stroke (HR&#x2009;=&#x2009;0.27, 95% CI [0.02, 3.92], <i>P</i>&#x2009;=&#x2009;.13), but it significantly reduced the occurrence of major vascular events (HR&#x2009;=&#x2009;0.65, 95% CI [0.43, 0.98], <i>P</i>&#x2009;=&#x2009;.04). However, OACs significantly increased the risk of recurrent ICH (HR&#x2009;=&#x2009;4.05, 95% CI [1.62, 10.17], <i>P</i>&#x2009;=&#x2009;.003) and major bleeding events (HR&#x2009;=&#x2009;3.70, 95% CI [1.64, 8.35], <i>P</i>&#x2009;=&#x2009;.002). No significant effect was observed on stroke or vascular death (HR&#x2009;=&#x2009;0.74, 95% CI [0.39, 1.41], <i>P</i>&#x2009;=&#x2009;.36).ConclusionsOACs can reduce the risk of major vascular events, but they significantly increase the risk of bleeding, particularly recurrent ICH. Clinical decision-making should be individualized, carefully evaluating the thromboembolic and bleeding risks for each patient. Further high-quality RCTs are needed to validate these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guangjing</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Sanming, Fujian Medical University, Sanming, Fujian, China.</Affiliation><Identifier Source="RINGGOLD">117895</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yipeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Sanming, Fujian Medical University, Sanming, Fujian, China.</Affiliation><Identifier Source="RINGGOLD">117895</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Luxia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Sanming, Fujian Medical University, Sanming, Fujian, China.</Affiliation><Identifier Source="RINGGOLD">117895</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0005-4757-5041</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Sanming, Fujian Medical University, Sanming, Fujian, China.</Affiliation><Identifier Source="RINGGOLD">117895</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Sanming, Fujian Medical University, Sanming, Fujian, China.</Affiliation><Identifier Source="RINGGOLD">117895</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Appl Thromb Hemost</MedlineTA><NlmUniqueID>9508125</NlmUniqueID><ISSNLinking>1076-0296</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020300" MajorTopicYN="Y">Intracranial Hemorrhages</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">intracranial hemorrhage</Keyword><Keyword MajorTopicYN="N">oral anticoagulants</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>3</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40836668</ArticleId><ArticleId IdType="pmc">PMC12374039</ArticleId><ArticleId IdType="doi">10.1177/10760296251368889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu W, Ye Z, Chen S, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients. Stroke. 2021;52(4):1225-1233. doi: 10.1161/STROKEAHA.120.031007</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.120.031007</ArticleId><ArticleId IdType="pubmed">33596677</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee Members; Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines [published correction appears in J Am Coll Cardiol. 2024 Mar 5;83(9):959. doi: 10.1016/j.jacc.2024.01.020.] [published correction appears in J Am Coll Cardiol. 2024 Jun 25;83(25):2714. doi: 10.1016/j.jacc.2024.05.033.]. J Am Coll Cardiol. 2024;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.08.017</ArticleId><ArticleId IdType="pmc">PMC11104284</ArticleId><ArticleId IdType="pubmed">38043043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko D, Chung MK, Evans PT, Benjamin EJ, Helm RH. Atrial fibrillation: A review. JAMA. 2025;333(4):329-342. doi: 10.1001/jama.2024.22451</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.22451</ArticleId><ArticleId IdType="pmc">PMC11774664</ArticleId><ArticleId IdType="pubmed">39680399</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher N, Metzner A, Kirchhof P. Anticoagulation in patients with low-burden atrial fibrillation: new evidence focussing on device-detected AF. Heart. Published online April 2025;29. doi: 10.1136/heartjnl-2024-324848</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2024-324848</ArticleId><ArticleId IdType="pubmed">40306759</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga M. Early antithrombotic therapy in acute ischemic stroke. J Neuroendovasc Ther. 2025;19(1):2024-0001. doi: 10.5797/jnet.ra.2024-0001</Citation><ArticleIdList><ArticleId IdType="doi">10.5797/jnet.ra.2024-0001</ArticleId><ArticleId IdType="pmc">PMC11826348</ArticleId><ArticleId IdType="pubmed">39958461</ArticleId></ArticleIdList></Reference><Reference><Citation>Komen JJ, Potteg&#xe5;rd A, Mantel-Teeuwisse AK, et al. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: A multicentre observational study. Eur Heart J. 2022;43(37):3528-3538. doi: 10.1093/eurheartj/ehac111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac111</ArticleId><ArticleId IdType="pmc">PMC9547505</ArticleId><ArticleId IdType="pubmed">35265981</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae176</ArticleId><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [published correction appears in Europace. 2021 Oct 9;23(10):1676. doi: 10.1093/europace/euab157.]. Europace. 2021;23(10):1612-1676. doi: 10.1093/europace/euab065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euab065</ArticleId><ArticleId IdType="pmc">PMC11636576</ArticleId><ArticleId IdType="pubmed">33895845</ArticleId></ArticleIdList></Reference><Reference><Citation>Boe NJ, Hald SM, Jensen MM, et al. Major cardiovascular events after spontaneous intracerebral hemorrhage by hematoma location. JAMA Netw Open. 2023;6(4):e235882. Published 2023 Apr 3. doi: 10.1001/jamanetworkopen.2023.5882</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.5882</ArticleId><ArticleId IdType="pmc">PMC10077102</ArticleId><ArticleId IdType="pubmed">37017964</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Murthy SB. Cardiovascular events after intracerebral hemorrhage. Stroke. 2022;53(7):2131-2141. doi: 10.1161/STROKEAHA.122.036884</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.122.036884</ArticleId><ArticleId IdType="pmc">PMC9247019</ArticleId><ArticleId IdType="pubmed">35674043</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: A guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361. doi: 10.1161/STR.0000000000000407</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0000000000000407</ArticleId><ArticleId IdType="pubmed">35579034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes MA, Rabinstein AA. Anticoagulation for atrial fibrillation after intracranial hemorrhage: A systematic review. Neurol Clin Pract. 2018;8(1):48-57. doi: 10.1212/CPJ.0000000000000425</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000425</ArticleId><ArticleId IdType="pmc">PMC5839688</ArticleId><ArticleId IdType="pubmed">29517050</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol. 2017;82(5):755-765. doi: 10.1002/ana.25079</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25079</ArticleId><ArticleId IdType="pmc">PMC5730065</ArticleId><ArticleId IdType="pubmed">29028130</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Qin M. Anticoagulation strategy in atrial fibrillation patients after intracranial hemorrhage. Adv Cardiovasc Dis. 2018;39(2):169-172. doi: 10.16806/j.cnki.issn.1004-3934.2018.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.16806/j.cnki.issn.1004-3934.2018.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JG, Cardus B, Klijn CJM, et al. Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges. J Neurol Neurosurg Psychiatry. Published online June 21, 2022. doi: 10.1136/jnnp-2020-325249</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325249</ArticleId><ArticleId IdType="pubmed">35728935</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L, Hu J, Yang P, Chen Q. Early vs later non-vitamin K antagonist oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation: A meta-analysis and systematic review of randomized trials. Heart Rhythm. 2025;22(3):629-636. doi: 10.1016/j.hrthm.2024.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2024.12.008</ArticleId><ArticleId IdType="pubmed">39672479</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Hou Y, Liu W, Liu M. Effect of oral anticoagulation therapy in atrial fibrillation patients with a history of intracranial hemorrhage: A systematic review and meta-analysis. Ann Palliat Med. 2022;11(10):3063-3074. doi: 10.21037/apm-22-582</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-22-582</ArticleId><ArticleId IdType="pubmed">35948473</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang XY, Zhang JY, Yu CY. Whether it is safe to start anticoagulation after intracranial hemorrhage within 2 weeks: A systematic review and meta-analysis. Ibrain. 2022;8(3):377-388. Published 2022 Aug 19. doi: 10.1002/ibra.12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibra.12060</ArticleId><ArticleId IdType="pmc">PMC10528763</ArticleId><ArticleId IdType="pubmed">37786745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi: 10.7326/0003-4819-146-12-200706190-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-146-12-200706190-00007</ArticleId><ArticleId IdType="pubmed">17577005</ArticleId></ArticleIdList></Reference><Reference><Citation>Metelli S, Chaimani A. Challenges in meta-analyses with observational studies. Evid Based Ment Health. 2020;23(2):83-87. doi: 10.1136/ebmental-2019-300129</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ebmental-2019-300129</ArticleId><ArticleId IdType="pmc">PMC10231593</ArticleId><ArticleId IdType="pubmed">32139442</ArticleId></ArticleIdList></Reference><Reference><Citation>Luc&#xe0; F, Colivicchi F, Oliva F, et al. Management of oral anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation. Front Cardiovasc Med. 2023;10:1061618. Published 2023 May 25. doi: 10.3389/fcvm.2023.1061618</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1061618</ArticleId><ArticleId IdType="pmc">PMC10249073</ArticleId><ArticleId IdType="pubmed">37304967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Caravaca JM, Esteve-Pastor MA, Camelo-Castillo A, et al. Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: An overview of the pharmacotherapy. Expert Opin Pharmaco. 2020;21(15):1867-1881. doi: 10.1080/14656566.2020.1789099</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2020.1789099</ArticleId><ArticleId IdType="pubmed">32658596</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews [published correction appears in Rev Esp Cardiol (Engl Ed). 2022 Feb;75(2):192. doi: 10.1016/j.rec.2021.10.019.]. Declaraci&#xf3;n PRISMA 2020: Una gu&#xed;a actualizada para la publicaci&#xf3;n de revisiones sistem&#xe1;ticas [published correction appears in Rev Esp Cardiol (Engl Ed). 2022 Feb;75(2):192. doi: 10.1016/j.rec.2021.10.019.]. Rev Esp Cardiol (Engl Ed). 2021;74(9):790-799. doi: 10.1016/j.rec.2021.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2021.07.010</ArticleId><ArticleId IdType="pubmed">34446261</ArticleId></ArticleIdList></Reference><Reference><Citation>Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. J Med Libr Assoc. 2021;109(2):174-200. doi: 10.5195/jmla.2021.962</Citation><ArticleIdList><ArticleId IdType="doi">10.5195/jmla.2021.962</ArticleId><ArticleId IdType="pmc">PMC8270366</ArticleId><ArticleId IdType="pubmed">34285662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366:l4898. Published 2019 Aug 28. doi: 10.1136/bmj.l4898</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Collaboration. Cochrane Handbook for Systematic Reviews: Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (Apache-AF). John Wiley &amp; Sons; 2022, Version 6.2, Chapter 4.</Citation></Reference><Reference><Citation>Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in The Netherlands (APACHE-AF): A randomised, open-label, phase 2 trial. Lancet Neurol. 2021;20(11):907-916. doi: 10.1016/S1474-4422(21)00298-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00298-2</ArticleId><ArticleId IdType="pubmed">34687635</ArticleId></ArticleIdList></Reference><Reference><Citation>SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: A randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol. 2021;20(10):842-853. doi: 10.1016/S1474-4422(21)00264-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00264-7</ArticleId><ArticleId IdType="pubmed">34487722</ArticleId></ArticleIdList></Reference><Reference><Citation>Veltkamp R, Korompoki E, Harvey KH, et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): A multicentre, open-label, randomised, phase 3 trial [published correction appears in Lancet. 2025 Mar 15;405(10482):896. doi: 10.1016/S0140-6736(25)00466-0.]. Lancet. 2025;405(10482):927-936. doi: 10.1016/S0140-6736(25)00333-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(25)00333-2</ArticleId><ArticleId IdType="pubmed">40023176</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Shahi Salman R, Stephen J, Tierney JF, et al. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): Prospective, individual participant data meta-analysis of randomised trials. Lancet Neurol. 2023;22(12):1140-1149. doi: 10.1016/S1474-4422(23)00315-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(23)00315-0</ArticleId><ArticleId IdType="pubmed">37839434</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>